The cheaper of the two rival macular degeneration treatments could lead to blindness or other adverse events, new research determined.
The Food and Drug Administration has approved a new drug for the treatment of the wet form of age-related macular degeneration, called Eylea. Macular degeneration is the leading cause of severe vision loss in the elderly.
Injections of the cancer drug Avastin, which is also a treatment for the wet form of age-related macular degeneration, has been linked to reports of blindness.
Further legislation is needed to empower the federal government to negotiate lower prescription drug prices in Medicare, a bipartisan panel concluded Thursday.
The cancer drug Avastin could be as effective as the more expensive Lucentis at improving the vision of seniors with macular degeneration, according to a report from The New York Times.